TG THERAPEUTICS INC. - COMMON STOCK

33,09

07-февраля-25 16:45:00

15 мин. задержка

Акции

-0,41

-1,22%

Сегодняшний диапазон

32,71 - 34,20

ISIN

N/A

Источник

NASDAQ

TG Therapeutics Announces European Launch of BRIUMVI® (ublituximab-xiiy)

26 фев 2024 07:00:00 Источник Nasdaq GlobeNewswire
TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2023 Financial Results and Business Update

23 фев 2024 07:30:00 Источник Nasdaq GlobeNewswire
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

20 фев 2024 07:30:00 Источник Nasdaq GlobeNewswire
TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones

10 янв 2024 07:00:00 Источник Nasdaq GlobeNewswire
TG Therapeutics Announces Global License Agreement with Precision BioSciences for the Development and Commercialization of Precision’s Allogeneic CD19 CAR T Cell Therapy Program for the Treatment of Autoimmune Diseases

09 янв 2024 07:00:00 Источник Nasdaq GlobeNewswire
TG Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

05 янв 2024 07:30:00 Источник Nasdaq GlobeNewswire
TG Therapeutics to Participate in the 6th Annual Evercore ISI HealthCONx Conference

27 ноя 2023 07:30:00 Источник Nasdaq GlobeNewswire
TG Therapeutics to Participate in the 5th Annual Guggenheim Inflammation, Neurology & Immunology (INI) Conference

03 ноя 2023 07:30:00 Источник Nasdaq GlobeNewswire
TG Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results

01 ноя 2023 07:30:00 Источник Nasdaq GlobeNewswire
TG Therapeutics to Host Conference Call on Third Quarter 2023 Financial Results and Business Update

30 окт 2023 07:30:00 Источник Nasdaq GlobeNewswire
TG Therapeutics Announces Presentation of Data for BRIUMVI at the 2023 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting

12 окт 2023 11:00:00 Источник Nasdaq GlobeNewswire
TG Therapeutics Announces Presentation of Data for BRIUMVI at the 2023 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting

11 окт 2023 10:30:26 Источник Nasdaq GlobeNewswire
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI at the 2023 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting

02 окт 2023 07:30:00 Источник Nasdaq GlobeNewswire
TG Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference

22 сен 2023 07:30:00 Источник Nasdaq GlobeNewswire
TG Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results

01 авг 2023 07:15:00 Источник Nasdaq GlobeNewswire
TG Therapeutics and Neuraxpharm Announce Ex-US Commercialization Agreement for BRIUMVI® (ublituximab-xiiy)

01 авг 2023 07:00:01 Источник Nasdaq GlobeNewswire
TG Therapeutics to Host Conference Call on Second Quarter 2023 Financial Results and Business Update

31 июл 2023 08:30:00 Источник Nasdaq GlobeNewswire
TG Therapeutics to Participate in the 2023 Jefferies Healthcare Conference

05 июн 2023 07:30:00 Источник Nasdaq GlobeNewswire
TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the 2023 Consortium of Multiple Sclerosis Centers Annual Meeting

02 июн 2023 09:15:20 Источник Nasdaq GlobeNewswire
TG Therapeutics Announces European Commission Approval for BRIUMVI® (ublituximab-xiiy) for the Treatment of Relapsing Forms of Multiple Sclerosis in Adults

01 июн 2023 09:15:00 Источник Nasdaq GlobeNewswire

<<
<
1
2
3
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.